Across 14 glioma stem cell lines and four synergy models, the synergy vs. CSS scores indicate a range of ‘good-to-potent’ additivity using a FAK+MEK inhibitor combination, with synergy observed in some GBM stem cell lines. The gene discussed is MAP2K7; the disease is central nervous system cancer.